Introduction

1
Cambodia, especially the western border with Thailand, is known as the multi-drug 2 resistant malaria hotspot. Pyrimethamine resistance was first reported on that border area in the 3 early 1950s (27), followed by chloroquine resistance in the late 1950s, sulfadoxine-4 pyrimethamine (SP) resistance in the late 1960s, and mefloquine resistance in the late 1980s 5 (31). Since 1986 (5), the Cambodian National Malaria Control Program (NMCP) has set up a 6
program to monitor the efficacy of SP and mefloquine monotherapy, specifically in the provinces 7 bordering Thailand, Vietnam and Laos. Between 1995 and 1999, failure rates based on 14-day 8 follow-up periods were 7-30% for a low dose mefloquine (15 mg/kg), and 7-10% for the higher 9 doses (20-25 mg/kg of mefloquine) in provinces in the northwest bordering Thailand, while the 10 efficacy remained 100% elsewhere (Denis MB, personal communication). These findings were 11 consistent with previous reports from Thailand (21) . In 2000, studies of the clinical efficacy of 12 artesunate-mefloquine (AM) (12 mg/kg artesunate and mefloquine 1000 mg were given over 3 13 days) were conducted, again in north-western Cambodia and confirmed 100% efficacy based on 14 a 14-day follow-up (Denis MB, personal communication). NMCP decided to switch to AM 15 combination therapy in the same year. antimalarial agents. Each plate included two drug-free control wells and one control well 5 without parasites. The culture plates were incubated for 48 hr at 37°C in a candle jar. [
3 H]-6 hypoxanthine (0.5 µCi/well; Amersham Biosciences, France) was used to assess parasite growth. 7
Each isolate was tested in duplicate in microplates with serial dilutions of drugs. Drug response 8 was quantified by measuring [
3 H]-hypoxanthine uptake in a Wallac MicroBeta Trilux counter 9 (Perkin-Elmer, France). At the end of the incubation period, the plates were frozen at -20°C and 10 thawed to lyse the cells. After collection on glass-fiber filter paper using a cell harvester, the 11 amount of [ 3 H]-hypoxanthine incorporated into parasite nucleic acids was determined. The 12 results of the in vitro assay are expressed as the 50% inhibitory concentration (IC 50 ), defined as 13 the concentration at which 50% of the incorporation of [ 3 H]-hypoxanthine was inhibited by 50% 14 of the drug-free control wells. Parasite growth was measured by using a log probit 15 approximation to determine the IC 50 values. 16
17
MOLECULAR ASSAYS 18
DNA extraction 19
Parasite DNA was extracted from frozen blood aliquots (200µl) using High Pure PCR 20 template preparation kit (Roche®, Roche Diagnostics Gmbh, Mannheim, Germany) following 21 the manufacturers protocol. Blood stored on filter paper was extracted using QIAamp DNA 22
Genetic polymorphism 1
Paired samples taken at enrolment and at recurrence of parasitaemia were used to 2 distinguish between recrudescence and re-infection. The number of variants in three 3 polymorphic genes (msp1, msp2 and glurp) was determined as described previously (11, 25) . If 4 the sample taken at recurrence contained either a subset of, or the same variants as the enrolment 5 specimen, the infection was classified as recrudescence. If not, the infection was classified as a 6 re-infection. The amplification of a single fragment at these three loci indicated that the parasite 7 population was mono-infected (single genotype). Detection of two or more PCR bands, at one or 8 more loci, indicated that the isolate contained multiple infections. 9
Nine SNPs of four genes: pfdhfr codons N51I, C59R, S108N/T, I164L; pfcrt codon 10 K76T; pfmdr1 codons N86Y, Y184F, N1042D and pfatpase6 codon S769N were analysed using 11 a microarray-based assay as described (4). Cut-off values were determined by an algorithm 12 including absolute signal and relative (green/red) values of optical densities. Each signal was 13 classified either as wild type or mutant (mixed was group as mutant) based on the expression 14 intensities of the scanned image. Controls included previously sequenced samples and the 3D7 15 strain. 16
17
STATISTICAL ANALYSIS 18
All statistical analyses were performed using Stata SE 8 (Stata Corporation, College 19 Station, Texas). Information on location, age, sex, parasitaemia and clinical outcome was 20 collected in an anonymous database. The in vitro activity of the antimalarials was expressed as 21 the geometric mean of the IC 50 for all isolates. Drug concentrations were transformed into 22 logarithms. The Wilcoxon rank-sum (Mann-Whitney) test was used to determine whether the 23 observed differences in the in vitro responses to antimalarial drugs or treatment failure were 1 significant. Linear regression analysis was used to assess the relationship between age, sex, the 2 prevalence of parasite and pfmdr1 polymorphisms. The level of significance was adjusted using 3 the Bonferroni correction. For all statistical tests, the significance level was set at p=0.05. There were marked differences in the study subject demographics between the eastern 19 and western sites. The median age was lower (17 vs 22, p<0.001, by Wilcoxon rank-sum 20 (Mann-Whitney) test) and the proportion of male participants lower (0.6 vs 0.7, p<0.001, by χ2 21 test) in the east than in the west. However, the geometric mean parasitaemia was slightly higher 22 for the west than the east (0.28% vs 0.23%, p= 0. The GMIC 50 for all four tested drugs were significantly higher in the western than in the eastern 14 provinces (p<0.001) ( Table 3) . 15 There were important differences in the GMIC 50 over time during the study period for a microarray analysis of gene polymorphism in four genes (pfdhfr, pfcrt, pfmdr1 and 11 pfatpase6). Interpretable results ranged from 52.4% for pfmdr1 N1042D to 92.8% for pfmdr1 12 N86Y. Table 9 summarizes the microarray results. Out of the 9 SNPs tested, 7 showed a 13 mutation frequency greater than 5% (Figure 3 ). Of these, we observed 3 SNPs which showed a 14 significant difference in their distributions between eastern and western Cambodia (pfdhfr N51I, 15
I164L and pfmdr1 Y184F). 16
We did not find any SNPs showing a significant association either with year, 17 parasitaemia, age, sex or the clinical outcome following AM therapy. Pfmdr1 codon Y184F 18 (N=114, p<0.001) and pfdhfr codon I64L (N= 162, p=0.02) showed a significant association with 19 elevated chloroquine GMIC 50 and pfmdr1 codon Y184F was found to be associated with an 20 increased level of artesunate GMIC 50 (N=113, p=0.003), but only for eastern Cambodia. Malaria control was particularly successful along the Cambodian-Thai border and the malaria 4 prevalence in that area is currently very low, an observation that is supported by the small 5 number of isolates showing multiple infections. More than 82% of the isolates contained only 6 one parasite population, with a single genotype at the msp1, msp2 and glurp loci and the mean 7 number of clones per isolate was only 1.18 (12). 8
Currently, there are several protocols for in vitro susceptibility assays of antimalarial 9 drugs, with a concerted attempt to standardize the protocols. Here, the tests were performed 10 following the recommendation of the WHO expert group for parasite culture, drug dilution and 11 analysis (2). IC 50 results for the four drugs tested against a 3D7 cultured strain are in the range 12 of acceptable values (Table 10 ). All susceptibility assays were done under the same conditions 13 (same group of technicians, equipment and reagents) and the raw data were analysed together 14 using the same software. Moreover, the in vitro tests were conducted at the same time, in 15 isolates collected from western and eastern Cambodia, thus comparison of the data by time and 16 place of sampling in this study is valid. 17
Our results show epidemiological differences between the eastern and western malaria 18 endemic areas. For example, at the western sentinel sites there were significantly more young 19 men (fewer children). These are explained by the fact that malaria in western Cambodia is more 20 occupationally related. Adults tended to get exposed to malaria during their jungle trips while 21 transmission in the villages is less and less common as malaria control is more successful in 22 Previous studies showed that pfmdr1 copy number and mutation in codon 184 were both 20 more prevalent in western than eastern Cambodia (23). Analysis of pfmdr1 copy number was 21 also conducted in our laboratory and reported earlier (12). According to that report, the 22 correlation between increased pfmdr1 copy number and increased mefloquine IC 50 was 23 on September 12, 2017 by guest http://aac.asm.org/ Downloaded from statistically significant. However, we did not find a statistically significant correlation between 1 increased pfmdr1 copy number and increased artesunate IC 50. Although the relationship between 2 pfmdr1 copy number and artesunate in vitro sensitivity has been shown experimentally (24), field 3 studies do not always demonstrate that relationship (9, 19) thus raising the suspicion that current 4 in vitro assay methods may not be sensitive enough for detecting a change in artemisinin 5 susceptibility levels in the field. 6
We confirm here the higher frequency of the pfmdr1 184F mutant in western Cambodia. However, we are aware that these preliminary conclusions need to be substantiated with a robust 2 population genetics study. 3
The positive correlation detected among the antimalarial drugs including amino-alcohols, 4 is consistent with previous reports (3, 13, 18) thus reflecting an alarming multi-drug resistant 5 phenotype. It should be noted that the decreasing in vitro susceptibility observed in isolates from 6 western Cambodia applied not only to drugs currently in operational use as the first line therapy 7 against P. falciparum (i.e. artesunate and mefloquine) but also chloroquine (only used for P. 8 vivax) and quinine (the second line drug against P. falciparum). 9
In vitro drug susceptibility monitoring can be beneficial to a malaria control program in 10 providing supportive data for the determination and prediction of the spread of resistance. In 11 eastern Cambodia, the 2007 data showed a significant increase in the level of the GMIC 50 for the 12 four drugs tested compared to the previous years. This trend is alarming as it suggests, 13 particularly for mefloquine and artesunate, the deteriorating efficacy of these drugs that is no 14 longer restricted to the Cambodian-Thai border but may be happening in other endemic areas in Tables   7   Table 1 -Sample size of in vitro drug susceptibility tests by year and sentinel site 8 
